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AbstractTitle:  Effect of Intraoperative Dexmedetomidine Infusion on Perioperative 
Opioid Use 
Background:  A 71-year-old female patient presented for robotic right hemicolectomy. The 
patient had a history of colon cancer, hypertension, and allergies to penicillin and propofol. The 
decision was made to approach the anesthetic plan with Enhanced Recovery After Surgery 
(ERAS) protocols in place. These protocols are intended to decrease or eliminate opioids, guide 
goal-directed fluid management, and speed recovery after surgery. Dexmedetomidine infusion 
was added as an adjunct to this protocol, and the patient was followed to assess opioid 
consumption post-operatively. 
Purpose: To evaluate current data related to dexmedetomidine infusion to make evidence-based 
recommendations on the use of the drug for perioperative purposes.  
Process: A systematic literature review was carried out using the University of North Dakota’s 
Library of the Health Sciences. Databases used include Cochrane, PubMed, and searches of CDC 
statistics. The search was conducted using key words and publication date limits to include 
recent and applicable data. Literature was synthesized to develop recommendations for an 
evidence-based approach to use of perioperative dexmedetomidine.  
Results: Randomized control trials, systematic reviews, and case reports were included in the 
final synthesis of literature. The literature suggests that dexmedetomidine may be used as part of 
an opioid-sparing anesthetic technique. Some of the strongest evidence advocates for a 
dexmedetomidine/opioid PCA post-operatively to decrease post-operative opioid consumption.  
Implications:  ERAS protocols are well-established as methods to increase patient satisfaction, 
decrease opioid consumption, and improve patient outcomes. Higher quality future research is 
needed to determine if dexmedetomidine should be used as an analgesic adjunct. Initial studies 
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suggest that dexmedetomidine infusion is a viable adjunct for opioid-sparing anesthetic 
techniques. 
Keywords: Dexmedetomidine, ERAS, opioid-sparing, pain 
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EFFECT OF INTRAOPERATIVE DEXMEDETOMIDINE INFUSION ON  
PERIOPERATIVE OPIOID USE 
 
Background 
Epidemiologic data presented by the Center for Disease Control and Prevention (CDC) 
reports that in 2015, there were 174.6 per 100,000 non-fatal drug-related overdoses brought to 
Emergency Rooms (ERs) in the United States. Of these, opioids had the highest incidence, 
followed by heroin, methadone, and “other opioids”, with all of these making up just over 50% 
of the total ER visits. Similarly, the CDC reported that 42,249 opioid-related overdose deaths 
occurred in 2016, which accounted for 66% of all drug-related deaths. What complicates this, 
and leads to great concern within the medical community, is that over 14,000 of those deaths 
(and possibly more) can be traced back to prescription opioids (CDC, 2018). Opioids are often 
prescribed to control post-operative pain. 
Opioids have been a reliable and effective form of perioperative pain control for 
hundreds of years, stemming from the historical use of the opium poppy. While effective, they 
do come with an undesirable array of side effects including nausea, vomiting, constipation, 
urinary retention, respiratory depression, and dependence (Nagelhout & Elisha, 2018). A recent 
study demonstrated that interventions anesthesia professionals utilized intraoperatively had the 
potential to decrease the opioid requirement post-operatively, even in those who are already 
opioid-dependent prior to surgery (Nielsen, Fomsgaard, Nikolajsen, Dahl, and Mathiesen, 2018).  
Opioids have been considered a primary analgesic in the practice of anesthesia due to 
both their efficacy in pain management and their low cost. This current opioid epidemic in the 
United States has created a unique situation for patients in the perioperative realm. Because the 
need exists for adequate intraoperative and post-operative pain control, anesthesia professionals 
must continue to consider opioid alternatives for analgesia. Enhanced recovery after surgery 
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(ERAS) protocols have begun to shape the way that anesthesia professionals approach their 
analgesic plans. In this paper, the author described current ERAS methods and sought to 
determine if there is a place for dexmedetomidine infusions within these protocols. Because of 
this, the author chose to research the question “In patients having outpatient surgery, does 
perioperative use of intravenous dexmedetomidine versus traditional opioid anesthesia produce 
decreased perioperative use of opioids?” 
Case Report 
A 71-year-old, 165 cm, 120 kg female patient presented for a robotic right 
hemicolectomy. Her past medical history included asthma, hypertension and LVEF of 55%, 
GERD, colon cancer, morbid obesity, and arthritis. Past surgical history included previous 
sigmoidectomy for colon cancer, as well as colonoscopy and esophagoduodenoscopy. Home 
medications included baby aspirin, losartan-hydrochlorothizide, multivitamin, and albuterol 
inhaler. She had drug allergies to penicillin, ketorolac, and propofol. Pre-anesthetic evaluation 
revealed history of post-operative nausea and vomiting, as well as history of difficult intubation. 
Airway evaluation showed a Mallampati score of 2, temporomandibular distance of greater than 
3 fingerbreadths, full neck range of motion, and intact dentition. Baseline vital signs were within 
normal limits. The patient was classified as an ASA Physical Status 3. An l8-gauge IV was 
started in the preoperative holding room with LR infusing by gravity.  
The patient was given midazolam 2 mg and taken back to the operating room. She was 
transferred to the operating room table and standard noninvasive monitors were attached along 
with bispectral index monitoring. The patient was preoxygenated with 15 liters per minute 100% 
O2 by mask. General anesthesia was induced with etomidate 12 mg, ketamine 30 mg, fentanyl 
100 mcg, lidocaine 50 mg, and rocuronium 50 mg. The patient was successfully intubated on the 
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first attempt with a Macintosh 3 blade (Grade II Cormack-Lehane view), 7.0 endotracheal tube 
with stylet. Endotracheal tube placement was confirmed with EtCO2 and bilateral breath sounds 
were auscultated. The tube was secured with tape, sevoflurane was initiated at ½ MAC, and fresh 
gas flows were decreased to O2 0.5 L/min and air 0.5 L/min. Magnesium 3g was bolused over 30 
minutes, and dexmedetomidine 0.5-0.7 mcg/kg/hr infusion was initiated along with lidocaine 
infusion at 1 mg/kg/hr LBW (60 mg/hr).  
Clindamycin 900 mg and Metronidazole 500 mg were initiated after induction, and 
dexamethasone 8 mg and ondansetron 4 mg were administered for PONV prophylaxis. Vital 
signs remained within normal limits throughout the case with the use of a phenylephrine 
infusion, as well as 25 mg total of ephedrine. Intravenous fluids totaled 1,600 ml with 180 ml of 
urine output, and an estimated blood loss of 50 ml. Per the facility’s ERAS protocol, ketamine 30 
mg was administered each hour throughout the case for a total of 120 mg. The patient was 
reversed with sugammadex 300 mg. An awake extubation was performed, with the patient 
stating comfort upon arrival to the post-anesthesia care unit. No narcotic medications were given 
in the immediate post-operative period.  
Post-operative pain control was discussed with the surgeon, and an agreement was made 
to put the patient on scheduled acetaminophen and gabapentin postoperatively with oxycodone-
acetaminophen tablets for breakthrough pain. Within 24 hours postoperatively, the patient had 
received only two narcotic doses for breakthrough pain.  
Methods 
A search of the current literature was performed on several resource databases through 
the University of North Dakota Health Sciences Library, including PubMed, ClincalKey, and 
Cochrane. Each search was limited to include articles in the English language less than five years 
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old, and studies related the adult human population (19+ years of age). These limits were chosen 
to obtain relevant, recent data on adult patients. MeSH keywords such as dexmedetomidine, 
analgesia, postoperative, opioid, anesthesia, opioid free, multimodal, and postoperative opioids 
were used. The date limits were increased to include all articles 15 years or newer related to 
“intravenous dexmedetomidine analgesia” due to lack of recent evidence specific to the 
intravenous route of administration. 
Cochrane database was searched to find Cochrane reviews and trials related to opioid-
free anesthesia using the search terms opioid AND free AND anesthesia, as well as 
dexmedetomidine AND analgesia. During this search, only 7 Cochrane reviews were returned, 
only one of which was relevant to the current topic of decreasing post-operative opioid use.  
Alternative websites were searched, including the American Association of Nurse 
Anesthetists website for position statements on opioid prescribing, the use of intraoperative and 
post-operative opioids, and opioid-free anesthesia. The United States Centers for Disease Control 
and Prevention website was searched for position statements on the opioid crisis, as well as 
epidemiologic data regarding drug poisonings and overdoses. Information was also found in a 
recently revised anesthesia textbook. Three total sources have been used outside of PubMed. 
Discussion 
Enhanced Recovery After Surgery 
Enhanced recovery after surgery, or ERAS, is a growing movement of improving patient 
outcomes and shortening hospital stays through judicious use of pharmaceuticals and patient care 
techniques. As anesthesia professionals, one of the main roles that we play in ERAS involves the 
use of multimodal analgesia (MMA) intraoperatively. Multimodal analgesia means the use of 
non-opioid analgesics, as well as balanced use of opioids, to achieve perioperative pain control. 
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Lavand’homme and Estebe (2018) discussed undesirable side effects of opioid analgesia, 
including opioid-induced hyperalgesia, post-operative nausea and vomiting, constipation, ileus, 
and dependence. According to these authors, the side effects of opioids can lead to long-term 
chronic pain, as well as prolonged hospital stay. 
Reagan, O’Sullivan, Gannon, and Steinberg (2017) explored the role of an opioid-free 
anesthetic (OFA) in post-operative opioid use for patients undergoing reconstructive pelvic 
surgery. In the randomized control study of 138 participants, MMA and opioid-sparing methods 
were found to provide equivalent pain control while decreasing post-operative opioid 
requirements. McLaughlin et al. (2018) found similar results when they paired multimodal 
analgesia with patients undergoing shoulder arthroplasty. Their prospective cohort study 
involved two groups of 75 participants each: one who received standard opioid anesthesia, and 
one who received a multimodal regimen. The multimodal group had lower pain scores on post-
operative day 0,1, and 2 (P < .01), as well as shorter hospital stays (P < .01), and had no more 
complications than traditional opioid analgesia. The shorter hospitalization described by 
McLaughlin et al. (2018) also provided for an average of $1,000 USD less in overall hospital 
costs for patients undergoing MMA. While the figure was not found to be statistically 
significant, it stands to reason that the average patient may consider this a benefit.  
So, what exactly is MMA? According to Brown, Pavone, and Naranjo (2018), this 
technique involves administering different drugs (with different mechanisms of action) together 
to achieve the anesthetized state. By doing this, the amount of each individual drug given is 
decreased versus a technique which uses only one or very few different agents. In the same way 
that a state of surgical anesthesia can be achieved with a multimodal approach, so can analgesia 
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during the perioperative period. To accomplish this, we must both define pain and understand the 
methods of pain transduction.  
Brown et al. (2018) made a clear distinction between the definition of pain and 
nociception. Pain is considered a conscious perception of painful stimuli whose severity depends 
on patient perception. This definition, while broad, is in congruence with the well-known 
definition saying that pain is “whatever the patient says it is.” Nociception is the actual 
transmission of painful stimulus within the nervous system. While nociception is sometimes 
what causes patients to perceive pain, it also can cause hemodynamic and humoral response 
changes such as hypertension, tachycardia, and cortisol release, even while patients are in the 
anesthetized state.  
Mechanisms of Pain Modulation 
Clarke et al. (2012) stated that pain can be classified as acute (less than 3 months 
duration) or chronic (lasting greater than 3-6 months). The cause of acute pain is generally 
known, which is what separates it from chronic pain, and these authors highlight the new 
knowledge that poorly treated surgical pain can be a precursor to chronic pain. Chronic post-
surgical pain can be prevented with a multimodal approach using neuraxial techniques, 
peripheral regional techniques, and drugs with multiple mechanisms of action. Ideally, pain 
management would be proactive, or anticipatory.  
Clarke et al. (2012) state that somatic and visceral pain are well-controlled by opioid 
analgesics, while neuropathic pain may be better treated by more unconventional pain 
medications such as antidepressants, gabapentinoids, muscle relaxants, and intravenous infusions 
such as lidocaine, ketamine, and dexmedetomidine.  
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Not all types of pain respond to the same pain medications. Lavond’homme and Estebe 
(2018) highlighted the multiple pathways and causes of nociception, including glutamate (fast 
onset, sharp pain), substance P (a peptide found in and released from peripheral afferent 
nociceptor C fibers), bradykinin, histamine, serotonin (5-HT), and prostaglandins among others, 
and discuss multimodal analgesic agents that may enhance both intraoperative and post-operative 
pain (Nagelhout & Elisha, 2018). With so many modes of pain transmission, it is important to 
note that the opioid pathway is only one of many that may be modulated to manage pain. 
Non-Opioid Analgesic Methods 
Ketamine. Ketamine is a phencyclidine that produces analgesia through antagonism of 
the N-methyl-D-aspartate (NMDA) receptor, as well as inhibition of mu, delta, and kappa opioid 
receptors. This drug generally provides analgesia and anesthesia without loss of respiratory 
reflexes (Nagelhout & Elisha, 2018). Aronsohn et al. (2018) wrote a case report on intraoperative 
use of ketamine to enhance analgesia for a morbidly obese patient (BMI 50.1 kg/m2) undergoing 
a laparoscopic gastric sleeve procedure. The patient presented for surgery with a history of 
obstructive sleep apnea (OSA), non-compliant with her CPAP. With the goal of avoiding adverse 
respiratory events related to narcotics, the authors used ketamine as part of an opioid-free total 
intravenous anesthesia protocol. The case proceeded with a ketamine loading dose of 5 mg/kg 
and a maintenance infusion of 5 mcg/kg/min. This case report states that the patient had 
comparable analgesia to an opioid technique, but had no episodes of apnea, hypoxia (SpO2 < 
93%), or airway obstruction in the PACU. In addition to meeting outcomes for respiratory 
function, the patient was also ambulating unassisted at 90 minutes post-op. 
There is evidence to show that intraoperative use of ketamine infusions is helpful for pain 
control, even in patients with chronic pain and opioid use. A randomized, double-blind study of 
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147 patients by Nielsen, Fomsgaard, Nikolajsen, Dahl, and Mathiesen (2018) showed that 
patients with chronic opioid-dependent pain undergoing spinal fusion have decreased use of 
opioids one year from surgery and have higher workforce association when intraoperative 
ketamine is used. While this does not relate immediately to postoperative or intraoperative 
analgesia, it shows that our nation’s opioid crisis can be combated partially by what anesthesia 
professionals do intraoperatively.  
Lidocaine. Boysen, Pappas, and Evans (2018) wrote a case comparison of two patients 
undergoing general anesthesia, one for bariatric surgery and one for endoscopic retrograde 
cholangiopancreatogram (ERCP). Both patients were administered intraoperative infusions of 
lidocaine and dexmedetomidine for pain control and sedation. As with many of the other studies, 
analgesics including subanesthetic doses of ketamine, as well as intravenous acetaminophen and 
ketorolac were used to maintain analgesia, and both patients were discharged having received no 
narcotics (Boysen, Pappas, & Evans, 2018). These examples, while few, are evidentiary to the 
possibility of a fully opioid-free anesthetic option, even for major surgeries such as bariatrics. 
Opioid-free analgesia can be achieved with modes such as these, in addition to administration of 
dexamethasone, selective cyclooxygenase-2 inhibitors such as celecoxib, and intravenous 
NSAIDS such as ketorolac can offer equivalent analgesia with potentially fewer undesirable side 
effects (Barazanchi, MacFater, Rahiri, Tutone, Hill, & Joshi, 2018). 
Dexmedetomidine. Intraoperative infusions of dexmedetomidine have become an area of 
interest for anesthetists looking to decrease perioperative narcotic administration. A prospective, 
randomized, double-blind trial by Bakan et al. (2015) explored the use of dexmedetomidine 
infusions in patients undergoing laparoscopic cholecystectomy. Eighty patients of physical status 
I-II were allocated into two groups, one opioid free with propofol, dexmedetomidine, and 
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lidocaine infusions, and one with remifentanil and propofol infusions. These authors found that 
while dexmedetomidine can result in slower waking times, it is also associated with significantly 
lower pain scores, fewer rescue analgesic, and fewer rescue anti-emetics.  
One of the most promising areas of research involves perioperative administration of 
dexmedetomidine, whether within intrathecal mixtures, nerve block mixtures, or as part of an 
intravenous anesthetic and analgesic cocktail. For the purposes of this case report, the 
intravenous method will receive primary focus as part of the MMA technique. 
Mechanism of action. Dexmedetomidine is a relatively selective alpha-2 agonist whose 
anti-nociceptive effects can be explained by stimulation of alpha-2 adrenoreceptors in the brain 
(locus coeruleus) and spinal cord, as well as hyperpolarization of interneurons and reduction of 
substance P and glutamate. The analgesic effect has been shown to be minimal at doses intended 
for light sedation. However, Weerink et al. (2017) found that the opioid-sparing effect stemming 
from altered perception and reduced anxiety may still be beneficial. Dexmedetomidine has the 
added benefit of providing sedative, anxiolytic, and antiemetic properties, even more so than its 
less-selective alpha-2 agonist relative, clonidine (Blaudszun et al., 2012). 
 Dexmedetomidine is rapidly distributed, with an initial distribution half-life of 6 minutes 
and a terminal elimination half-life of 2 hours. It is metabolized into only inactive metabolites 
and excreted primarily through hepatic and renal modalities. Because of this, the initial dose of 
dexmedetomidine should be decreased in patients with chronic hepatic or renal insufficiency, or 
those at risk for developing these conditions (Nagelhout & Elisha, 2018).  
 According to Weerink et al. (2017), dexmedetomidine hydrochloride is generally diluted 
to a concentration of 4 mcg/ml or 8 mcg/ml prior to infusion. The drug comes in two brand 
names; Dexdor and Precedex. Dexdor’s instructions state to start at an initial infusion rate of 0.7 
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mcg/kg/hr with no loading dose, and titrate to effect with dose range 0.2-1.4 mcg/kg/hr. 
Precedex’s instructions state to begin with a loading dose of 1 mcg/kg over 10 minutes, and 
follow with maintenance infusion of 0.2-0.7 mcg/kg/hr. Procedural sedation allows the same 
loading dose of 1 mcg/kg over 10 minutes, with dose range 0.2-1 mcg/kg/hr. 
 Dexmedetomidine is FDA approved for intravenous use for up to 24 hours. It is highly 
protein-bound, with 94% bound to albumin and alpha-1-glycoprotein in plasma. It easily crosses 
the blood-brain barrier and placenta, and the apparent volume of distribution is related to body 
weight. Ingrande and Lemmens (2010) discussed that dosing in the morbidly obese should often 
be based on lean body weight, but there are no specific recommendations for dosing 
dexmedetomidine infusions. Dexmedetomidine undergoes an extensive first-pass effect when 
given orally, leaving only 16% bioavailable. Intranasally, it is well-absorbed (Weerink et al., 
2017).   
Adverse effects. Coadministration of dexmedetomidine in addition to other anesthetic 
modalities such as propofol, inhaled agents, and opioids can lead to compounding hemodynamic 
effects including bradycardia and hypotension. A balanced technique should be used to avoid 
these potential adverse effects. 
Preoperative Applications 
 Pasin et al. (2015) provided a meta-analysis of dexmedetomidine versus midazolam for 
preoperative sedation in pediatrics. While this paper focuses on adult patients, it is worth noting 
that the authors noted the pediatric patients had significantly decreased anxiety on separation 
from the parents, decreased postoperative agitation, and more effective postoperative analgesia 
compared to midazolam. It should also be noted that the use of dexmedetomidine in pediatric 
patients is not FDA approved, and more research is required to gain approval for this use.  
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 According to Weerink et al. (2017), preoperative sedation can be achieved in pediatric 
patients and uncooperative elderly patients by means of intranasal dexmedetomidine. While this 
is not currently an FDA-approved method of administration for the drug, it has been shown to be 
effective due to bioavailability of the drug through mucosal membranes. More research would 
need to be done to determine dexmedetomidine’s usefulness in this way, and to determine 
whether this also has opioid-sparing effect.  
 Naaz and Ozair (2014) described a dosing regimen in their review of dexmedetomidine in 
practice. According to this review, a dose of dexmedetomidine 0.33-0.67 mcg/kg IV or 2.5 
mcg/kg IM may be given 15 minutes preoperatively for sedation and reduction of oxygen 
consumption. 
Intraoperative Applications 
 The subject of this case report was administered dexmedetomidine 0.5-0.7 mcg/kg/hr 
intraoperatively. While there are preoperative and postoperative indications for use of 
dexmedetomidine, the protocols at this hospital allowed only for intraoperative infusion. As 
stated previously, dexmedetomidine was used as an adjunct along with lidocaine 1 mg/min IV, as 
well as magnesium and ketamine boluses.   
 A meta-analysis by Singh et al. (2017) explored the role of intraoperative 
dexmedetomidine infusion for 24-hour post-operative analgesic requirements in obese patients 
undergoing bariatric surgery. The authors found that both intraoperative and postoperative 
infusions of dexmedetomidine resulted in an opioid-sparing effect in early and extended 
postoperative courses. These morbidly obese patient had not only improved pain control, but 
they also benefitted from lower incidence of postoperative nausea and vomiting than their 
placebo counterparts (Singh et al., 2017).   
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 Another study by Bielka, Kuchyn, Babych, Martycschenko, and Inozemtsev (2018) 
discussed the use of dexmedetomidine infusion of 0.5 mcg/kg/hr vs saline placebo from 
induction of anesthesia until extubation in a group of physical status 1-2 patients undergoing 
laparoscopic cholecystectomy. These authors found that patients had lower incidence of 
postoperative pain, longer time to first use of rescue analgesia, and an overall decrease in 
postoperative opioid consumption. 
 During cervical spine cases, it is imperative that the patient have an adequate airway for 
extubation, which can often mean careful titration of narcotics. Gandhi et al. (2017) conducted a 
randomized controlled trial of 60 patients, split into two groups. One received a 
dexmedetomidine loading dose of 1 mcg/kg over 10 minutes, followed by an intraoperative 
infusion of 0.5 mcg/kg/hr, followed by a reduced infusion of 0.2 mcg/kg/hr for 24 hours 
postoperatively. The second group received a volume matched bolus and infusion of saline. The 
authors found that the dexmedetomidine regimen decreased anesthetic requirement 
intraoperatively and provided effective analgesia postoperatively (Gandhi et al., 2017).  
 While there are studies looking at adding dexmedetomidine to regional anesthesia to 
prolong the duration of peripheral nerve blocks, some studies have shown that an intravenous 
bolus of the drug may also prolong block duration. Kang et al. (2018) conducted a prospective, 
double-blind, randomized controlled trial of 72 patients. The goal of the study was to determine 
first pain at surgical site in patients having interscalene block (ISB) for shoulder surgery. Each 
patient received an ISB with 15 ml 0.5% ropivacaine, and then four groups (n = 18 in each) were 
assigned to receive a 50 ml bolus over 30 minutes of either saline placebo, or dexmedetomidine 
0.5 mcg/kg, 1 mcg/kg, or 2 mcg/kg. The researchers determined that a 2 mcg/kg bolus provided 
superior block duration (p < 0.001) compared to the other groups.  
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 Lastly, Shin et al. (2018) conducted a randomized controlled trial in which 48 patients 
undergoing total knee arthroplasty with spinal anesthesia were split equally into two groups. The 
first group was given a 1 mcg/kg bolus of dexmedetomidine followed by an infusion of 0.1-0.5 
mcg/kg/hr for intraoperative sedation. The second group was given continuous propofol infusion. 
The dexmedetomidine sedation was associated with a small, but statistically significant 
difference in 24 and 48-hour post-operative opioid consumption.  
Postoperative Applications 
 Postoperatively, dexmedetomidine may be used in conjunction with narcotic analgesics 
to decrease the total amount of narcotic received and improve analgesic effect and subjective 
sleep quality. Li et al. (2018) conducted a pilot randomized controlled trial of 58 adults 60 years 
of age or older after open abdominal surgery. These authors found that the primary outcome, 72-
hour morphine consumption, was significantly lower when morphine patient-controlled analgesia 
was supplemented with dexmedetomidine versus morphine alone. The intervention group in this 
study received morphine 0.5 mg/ml with dexmedetomidine 2 mcg/ml in normal saline 100 ml. 
The patient-controlled analgesia was set to deliver a 2 ml bolus with an 8 minute lock-out period. 
Pertinent secondary outcomes were measured in this group, and pain intensity was significantly 
lower in the intervention group while sleep quality was significantly higher (Li et al., 2018).  
 The subject of this case study received no narcotic or other pain medication in PACU, 
and only two doses of oxycodone-acetaminophen 5-325 within 24 hours after surgery. She also 
had no significant post-operative hypotension or bradycardia. A Cochrane systematic review 
conducted by Lundorf, Nedergaard, and Moller (2016) included seven studies with a total of 492 
participants. Most of the studies found a decrease in rescue opioids within 24 hours after surgery, 
but no significant decrease in postoperative pain. This is still significant, as it means that there 
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has been a decrease in opioid consumption. The review also found an increased risk of post-
operative hypotension with high-dose infusions, relatively low risk with lower dose infusions.  
In addition to lowering perioperative narcotic requirements, postoperative nausea and 
vomiting was shown to be less in patients receiving dexmedetomidine versus placebo. This 
review stated the evidence to be very low to low due to the heterogeneity and potential bias of 
the studies included. The authors of this review point out that additional studies of higher quality 
should be done to determine the full scope of effect for perioperative dexmedetomidine.  
Recommendations 
Recommendation #1 
To improve patient experience and pain management, anesthesia professionals should 
administer preoperative membrane stabilizers (such as pregabalin or gabapentin), selective COX-
2 inhibitors (such as celecoxib or meloxicam), and acetaminophen when not contraindicated. 
This recommendation is backed by several high-quality studies that show preoperative 
administration of these medications can provide enhanced recovery after surgery. 
Recommendation #2 
Anesthesia professionals should consider using dexmedetomidine infusions in the 
intraoperative period to enhance pain control, control the stress response to surgery, and assist in 
sedation. Further studies are necessary to confirm its efficacy, but the initial evidence is showing 
good results and better immediate postoperative pain control with the use of dexmedetomidine 
infusions.  
Intravenous dexmedetomidine bolus of 2 mcg/kg over 30 minutes after induction may 
also have a role in prolonging the effects of peripheral and neuraxial anesthesia by increasing the 
time until first pain at surgical site requiring rescue analgesia. These techniques should be used 
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when prudent and possible to mitigate the use of intraoperative opioids and promote post-
operative pain control. This recommendation is based on Grade A evidence showing that for as 
long as the peripheral nerve block lasts, pain is well-controlled without opioids or with minimal 
opioid administration. Use of peripheral regional anesthesia allows for up to 24 hours of 
postoperative analgesia, depending on the local anesthetic agent used (Nagelhout & Elisha, 2018; 
Kang et al., 2018).  
Recommendation #3 
Further research is needed to determine the true value of intraoperative and post-
operative dexmedetomidine infusions for post-operative pain control. As ERAS protocols 
become more commonly used, a randomized controlled study for protocols with and without 
dexmedetomidine could be used. This would provide insight as to whether it is the other 
components of ERAS (such as lidocaine, ketamine, and magnesium) that are providing for 
improved pain management, or if dexmedetomidine itself has added benefit. Future research 
should also look to determine whether dexmedetomidine should be bolused and infused at total, 
ideal, or lean body weight, and whether there are specific effective dosing regimens for bolus 
and infusion.   
Conclusion 
While there are many non-opioid methods of analgesia that may be employed by a 
prudent anesthesia professional, the use of intraoperative infusion of dexmedetomidine should be 
considered when a multimodal analgesic technique is utilized to decrease opioid use and improve 
patient outcomes and satisfaction. This idea is consistent with the position statement made by the 
American Association of Nurse Anesthetists (AANA) regarding the opioid crisis in America. It 
is the responsibility of anesthesia professionals to collaborate with the interdisciplinary team to 
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create comprehensive post-operative pain management strategies. In doing this, the 
interdisciplinary team can decrease or eliminate the need for opioid pain medications throughout 
the perioperative period (AANA, 2018).  
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